Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹79Cr
Rev Gr TTM
Revenue Growth TTM
6.43%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

JHS
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | 13.7 | -25.4 | -10.1 | -35.6 | -0.3 | 54.0 | 4.0 | 58.5 | 16.2 | -4.2 | 13.2 | 2.7 |
| 25 | 18 | 19 | 14 | 21 | 23 | 21 | 22 | 31 | 22 | 21 | 22 |
Operating Profit Operating ProfitCr |
| -16.4 | -13.4 | 2.2 | -0.3 | 3.8 | 8.0 | -4.3 | 1.1 | -21.4 | 7.1 | 4.1 | 7.2 |
Other Income Other IncomeCr | -12 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | -1 | 1 | 1 | 1 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| -17 | -3 | -1 | 1 | 0 | 0 | -2 | -2 | -9 | 1 | 0 | 0 |
| -6 | -1 | 0 | 1 | 1 | 1 | 8 | 0 | -2 | 0 | 0 | -1 |
|
Growth YoY PAT Growth YoY% | -141.8 | 37.7 | 20.6 | 100.4 | 93.0 | 75.7 | -1,313.7 | -18,500.0 | -828.0 | 268.3 | 98.1 | 142.9 |
| -49.3 | -16.3 | -3.9 | 0.1 | -3.5 | -2.6 | -52.4 | -8.1 | -27.6 | 4.5 | -0.9 | 3.4 |
| -1.4 | -0.3 | -0.1 | 0.0 | -0.1 | -0.1 | -1.2 | -0.2 | -0.8 | 0.1 | 0.0 | 0.1 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| 56.8 | 80.9 | 5.0 | 33.5 | -11.6 | 12.2 | -27.6 | -14.4 | -1.7 | -16.5 | 29.9 | 2.4 |
| 59 | 94 | 93 | 127 | 125 | 137 | 99 | 87 | 94 | 72 | 96 | 95 |
Operating Profit Operating ProfitCr |
| -7.0 | 6.4 | 11.1 | 9.8 | -0.5 | 1.2 | 1.9 | -1.0 | -10.7 | -1.3 | -4.4 | -1.2 |
Other Income Other IncomeCr | -6 | -4 | 0 | 32 | 7 | 3 | 8 | 9 | -7 | 4 | 0 | 1 |
Interest Expense Interest ExpenseCr | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 1 |
Depreciation DepreciationCr | 12 | 10 | 6 | 7 | 7 | 9 | 7 | 7 | 6 | 6 | 8 | 8 |
| -22 | -22 | 5 | 38 | -2 | -6 | 1 | 0 | -23 | -3 | -13 | -8 |
| 0 | 0 | -17 | 12 | 0 | -1 | 0 | 4 | -5 | 1 | 7 | -3 |
|
| 23.0 | 2.4 | 201.4 | 18.8 | -106.4 | -191.2 | 127.7 | -419.5 | -308.4 | 76.8 | -386.6 | 73.1 |
| -40.1 | -21.6 | 20.9 | 18.6 | -1.3 | -3.5 | 1.3 | -5.0 | -20.6 | -5.7 | -21.5 | -5.6 |
| -9.1 | -8.3 | 5.4 | 4.5 | -0.1 | -0.3 | 0.2 | -0.6 | -2.3 | -0.5 | -2.4 | -0.7 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 24 | 38 | 44 | 61 | 61 | 61 | 64 | 65 | 78 | 78 | 86 | 86 |
| 96 | 57 | 86 | 113 | 116 | 117 | 124 | 121 | 95 | 91 | 85 | 88 |
Current Liabilities Current LiabilitiesCr | 49 | 18 | 20 | 32 | 39 | 48 | 23 | 19 | 37 | 23 | 25 | 25 |
Non Current Liabilities Non Current LiabilitiesCr | 1 | 2 | 1 | 2 | 2 | 8 | 7 | 8 | 18 | 4 | 4 | 9 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 43 | 36 | 43 | 103 | 102 | 130 | 121 | 79 | 85 | 44 | 54 | 59 |
Non Current Assets Non Current AssetsCr | 127 | 85 | 113 | 105 | 120 | 111 | 107 | 143 | 143 | 153 | 147 | 148 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 7 | -4 | -4 | 14 | -11 | 10 | 12 | -9 | 23 | -9 | -5 |
Investing Cash Flow Investing Cash FlowCr | 1 | 1 | -3 | -27 | -7 | -11 | -2 | -5 | 10 | -21 | -20 |
Financing Cash Flow Financing Cash FlowCr | -10 | 4 | 10 | 14 | 13 | 0 | 10 | -2 | -1 | 2 | 23 |
|
Free Cash Flow Free Cash FlowCr | 9 | -7 | -17 | 3 | -26 | 0 | 4 | -16 | 9 | -41 | -15 |
| -32.9 | 17.4 | -17.9 | 53.0 | 647.1 | -213.2 | 896.1 | 213.0 | -132.9 | 226.2 | 26.2 |
CFO To EBITDA CFO To EBITDA% | -187.7 | -58.6 | -33.6 | 100.4 | 1,833.6 | 619.0 | 627.0 | 1,086.2 | -256.7 | 979.2 | 129.1 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 18 | 85 | 173 | 327 | 168 | 46 | 128 | 133 | 102 | 128 | 96 |
Price To Earnings Price To Earnings | -0.8 | -3.9 | 7.9 | 12.5 | 0.0 | 0.0 | 105.0 | 0.0 | 30.2 | 0.0 | 0.0 |
Price To Sales Price To Sales | 0.3 | 0.8 | 1.6 | 2.3 | 1.4 | 0.3 | 1.3 | 1.6 | 1.2 | 1.8 | 1.0 |
Price To Book Price To Book | 0.1 | 0.9 | 1.3 | 1.9 | 0.9 | 0.3 | 0.7 | 0.7 | 0.7 | 0.8 | 0.6 |
| -9.3 | 12.9 | 14.3 | 23.4 | -293.7 | 31.6 | 59.6 | -158.2 | -7.3 | -131.5 | -20.6 |
Profitability Ratios Profitability Ratios |
| 27.0 | 26.9 | 36.3 | 35.8 | 29.9 | 28.4 | 32.2 | 29.9 | 28.8 | 37.6 | 33.6 |
| -7.0 | 6.4 | 11.1 | 9.8 | -0.5 | 1.2 | 1.9 | -1.0 | -10.7 | -1.3 | -4.4 |
| -40.1 | -21.6 | 20.9 | 18.6 | -1.3 | -3.5 | 1.3 | -5.0 | -20.6 | -5.7 | -21.5 |
| -15.9 | -22.1 | 4.4 | 22.3 | -0.6 | -2.1 | 1.1 | 0.8 | -12.7 | -1.7 | -6.8 |
| -18.5 | -22.9 | 16.9 | 14.9 | -0.9 | -2.7 | 0.7 | -2.3 | -10.1 | -2.4 | -11.6 |
| -13.1 | -17.9 | 14.1 | 12.5 | -0.8 | -2.0 | 0.6 | -1.9 | -7.7 | -2.1 | -9.8 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Overview**
JHS Svendgaard Laboratories Ltd. is India’s largest integrated oral care manufacturer and a leading private label and contract manufacturing partner for domestic and global FMCG brands. Established in 1996 (originally as Sunehari Svendgaard Laboratories) and incorporated in 2004, the company has evolved into a fully integrated, end-to-end FMCG manufacturing powerhouse. Listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) since 2006, JHS operates from a 20-acre, state-of-the-art manufacturing campus in Kala-Amb, Himachal Pradesh.
Under the leadership of Managing Director Nikhil Nanda, the company has transitioned from a toothbrush specialist to a diversified contract manufacturer across oral care, personal care, hygiene, and emerging FMCG categories.
---
### **Core Business Segments & Manufacturing Capabilities**
1. **Oral Care (Flagship Segment)**
- Products: Toothbrushes, toothpastes, mouthwashes, whitening gels, denture tablets.
- **Unique Integration**: JHS is the **only company globally** that manufactures both toothbrushes (mechanical process) and toothpastes (chemical process) on a single campus, enabling **10–20% cost savings** on combo packs and private label bundles.
- Capacity: Currently operating at ~70% utilization (up from ~25–30% in 2022) with significant room for scalable expansion.
2. **Personal & Home Care Diversification**
- Products: Talcum powders, hand sanitizers, laundry detergents, room fresheners, hair oils, lotions, shampoos, and soaps.
- **Talcum Powder**: Launched in 2023 with commercial tie-ups including Zydus Cadila’s **Nycil**, Amway, and Persona. Capacity **tripled in FY 2024–25**.
- **New Plant in Jammu & Kashmir**: A ₹30 crore greenfield project expected to generate up to ₹500 crore in annual revenue and boost EBITDA margins to over 20%.
3. **Proprietary Brand – Aquawhite™**
- Focus: Children’s oral care with licensed character tie-ups (e.g., **Peppa Pig, Pokémon, Chhota Bheem, Hello Kitty, SpongeBob SquarePants**).
- USP: Compliance-focused, fluoride-free formulations and “Brush-Mates” engagement concept.
- Marketing: “Two Two ka Formula” campaign to promote brushing habits. Among **top 3 kids’ oral care brands in Delhi-NCR** region.
---
### **Clients & Business Models**
- **Contract Manufacturing (B2B Focus):**
- Serves **30+ major FMCG clients** including:
- **Domestic**: Dabur, HUL (Close Up, Wheel), Patanjali, Reliance Retail, Apollo Pharmacy.
- **Global**: Amway, Boots, Walmart, Dr. Fresh, Gillette (Oral-B), Artsana Group (Chicco).
- Exclusively manufactures **Chicco-branded toothpaste and toothbrushes** for Artsana Group in India.
- Also produces for **e-commerce platforms** and **retail chains**.
- **Private Label Manufacturing:**
- Offers formulation development, packaging, and full production services under client brands.
- **Retail (via Subsidiary):**
- **JHS Svendgaard Retail Ventures Ltd.** operates airport, mall, and standalone retail stores.
- Turnover: ₹1,304.81 crores in FY24, ₹1,139.22 crores in FY23.
---
### **Strategic Growth Initiatives (FY 2025–2026)**
1. **Expansion & Investment**
- New **Jammu & Kashmir manufacturing facility** to enhance supply chain resilience and reduce costs.
- Exploring **southern India plant** for decentralized manufacturing proximity to GST-driven local sourcing demands.
- Expansion into **nutraceuticals, fast snacks, and cosmetics** under new FMCG diversification strategy.
2. **R&D & Innovation**
- In-house R&D center with capabilities in Ayurvedic and chemical formulations.
- Developed approved products for a **major US brand**, with plans to launch in export markets.
- 6-month stability testing creates a **barrier to entry** for competitors.
3. **Global Footprint & Exports**
- **Exports <1% of sales**, but strategically expanding:
- Partnered with **Orazen INC (New Jersey, USA)** to launch **PEPSODENT Triple Acon** toothbrushes.
- Secured export orders in **Dubai** via **Classico Brands (Inglish Popular Flexi)**.
- Participated in **COSMOPROF 2024, CMPL Expo Mumbai, CPHI Noida, Private Label Middle East Dubai**.
- Pursuing **FDA, ISO, GMP, SMETA certifications** for deeper global access.
4. **Merger & Synergy Strategy (Post-Vedic Merger Review)**
- While proposed merger with **Vedic Cosmeceuticals** did not materialize, the strategy of **cross-selling** between oral care and personal care remains key.
- Synergies expected with **existing clients** like Dabur to expand into skincare and hygiene categories.
---
### **Operational Excellence**
- **Manufacturing Infrastructure**:
- 6 production units: 3 for toothbrushes, 2 for toothpaste (Ayurvedic & cosmetic), 1 for talc.
- **7 high-speed filling lines** (120–150 TPM).
- Fully automated bristling lines (Belgium/Germany equipment).
- **Quality & Certifications**:
- ISO 9001, GMP, FDA, SMETA compliant.
- In-house QC lab with global testing standards.
- **Logistics Advantage**:
- Kala-Amb campus within **1 hour** of rail, air, road, and dry port hubs.
- 250,000 cubic feet warehouse capacity.
---
### **Financial & Market Highlights**
- **Revenue Growth**:
- 30% annual growth from FY23 to FY24 (**exceeding ₹92 crores**).
- Q2 FY2024 revenue: ₹18.93 crores (19% QoQ growth).
- **Profitability**:
- Strategic shift to high-margin clients improved **EBITDA margins by ~1500 bps** (from negative in FY21 to double-digit).
- Targeting **>20% EBITDA margin** post-Jammu expansion.
- **Balance Sheet**:
- **Nearly debt-free** (net debt-to-equity: 0.02 in FY22), with only minor vehicle loans.
- Strong cash flow for CAPEX and expansion.